NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.’s Innovative Approach to Gene Therapy

World News: . []

NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsAudio announces the Audio Press Release (APR) titled “Making Profits, Saving Lives with Gene Therapy,” featuring Genprex Inc. ().

To hear the NetworkNewsAudio version, visit:

To read the full editorial, visit:

Delivery systems for the genes are as important as the genes themselves. Carriers called vectors deliver the genetic material into the cells. These are often viruses, turning a life form that is hostile to humanity into one that benefits us. In the case of Genprex’s Oncoprex treatment, the genes are carried in an intravenously delivered nanovesicle, or a tiny compartment like those found in cells. The Oncoprex nanovesicle is small enough to cross barriers into the lungs, where it can deliver its genetic material to the cancer site.

This uses one of two forms of gene therapy: gene replacement therapy. Currently, . The alternative, gene editing, has been the subject of various clinical trials but has not yet led to an approved treatment. For now, gene replacement therapy, or tackling unhealthy cells through the addition of healthy genes, is the proven way forward to gene therapy, and the approach appears to be serving Genprex well.

Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, visit the company’s website at .

For more information, visit: 

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

NetworkWire (NW) New York, New York 212.418.1217 Office

More news and information about NetworkNewsWire

Published By:

Globe Newswire: 12:30 GMT Friday 15th March 2019

Published: .

Search for other references to "networknewsaudio" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us